Spending like a bigger company on purpose: current results carry the cost of an expansion aimed at demand management say
The model's full reasoning — Q4 2021 call → NOWe need to determine if the transcript contains both elements: (1) expansion already underway and visibly costing something now, and (2) justification based on demand already real, not just hoped for. Let's examine the transcript for mentions of expansion, costs, and demand. Key points: - John Fortson mentions "We continue to strategically invest in growth in our future. We completed alternative fatty acid production and saw the first sales of our new ALTAVEG product. We continue to assess other feedstocks and expect commercial sales to grow this year." This indicates expansion (alternative fatty acid production) completed, and sales already starting. But does it weigh on current results? Not explicitly stated as a cost burden. - Mary Hall mentions "Q4 inventory build in Performance Chemicals in anticipation of seasonal demand and continued strong volume growth resulted in free cash flow slightly below our guidance for the year." This is inventory build, which is a cost (cash flow) but it's for seasonal demand, not necessarily a new expansion. It's a routine inventory build. - John Fortson: "We will continue to invest organically, as we bring online our new polyol capability in DeRidder and an alternate fatty acid stream in Crossett." This is expansion underway, but does it weigh on current results? Not explicitly stated as a burden. - Also: "We are also in the execution phase of our SAP S/4HANA implementation. CapEx will be elevated somewhat from recent levels, but we consider these investments well worth the effort as they exceed our investment return expectations and will help us sustain our highly profitable growth." This is expansion (IT system) and CapEx elevated, but does it weigh on current profitability? Not directly stated as a burden on current results; it's just elevated CapEx. - Mike Smith mentions "We also sold non-CTO based alternative fatty acids as well as alternative fatty acid derivatives in Q4. We remain excited about the additional alternative fatty acid capacity at our Crossett facility coming online in early Q2 of this year to support more substantial future sales growth." This is expansion coming online, but not yet costing? It's future. - John Fortson: "We completed alternative fatty acid production and saw the first sales of our new ALTAVEG product." So that's already done and sales are happening.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| PUMP | ProPetro Holding Corp. | Q4 2023 | 2024-02-21 | C+ |
| PTLO | Portillo's Inc. | Q2 2023 | 2023-08-05 | B |
| AFL | Aflac Incorporated | Q2 2023 | 2023-08-02 | C+ |
| KE | Kimball Electronics, Inc. | Q3 2023 | 2023-05-06 | C+ |
| SIBN | SI-BONE, Inc. | Q3 2022 | 2022-11-07 | C+ |
| CHE | Chemed Corporation | Q3 2022 | 2022-11-01 | B+ |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| WD | Walker & Dunlop, Inc. | Q2 2022 | 2022-08-09 | C+ |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| FLYW | Flywire Corporation | Q1 2022 | 2022-05-14 | B+ |
| HLIO | Helios Technologies, Inc. | Q1 2022 | 2022-05-10 | C |
| IRTC | iRhythm Technologies, Inc. | Q1 2022 | 2022-05-07 | C+ |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
| LMAT | LeMaitre Vascular, Inc. | Q3 2021 | 2021-10-29 | C+ |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| JBT | John Bean Technologies Corporation | Q2 2018 | 2018-07-26 | B |
| CP | Canadian Pacific Railway Limited | Q2 2018 | 2018-07-19 | B+ |
| AOSL | Alpha and Omega Semiconductor Limited | Q2 2018 | 2018-02-07 | B |
| IR | Ingersoll-Rand Plc | Q3 2017 | 2017-10-25 | B |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
SIBN · Q3 2022 → YESThe question is: Does management acknowledge that the company's CURRENT reported results are being visibly weighed down by the cost of an expansion the company has ALREADY undertaken — spending, hirin...YES Management explicitly describes the expansion as already underway and costing the company now: investments in sales force (85 territory managers + 72 specialists), new products (iFuse-TORQ, iFuse-Bedrock Granite), instrument trays, inventory, and R&D that are driving higher depreciation, freight, and product costs 84% gross margin (down low-single digits from these factors). Anshul confirms “we’ve made a substantial amount of investment whether it’s in TORQ trays or Granite trays or TORQ implants” and “this is going to lead to elevated depreciation,” while Laura notes the build supports “strong new product demand.
FLYW · Q1 2022 → YESThe question is: Does management acknowledge that the company's CURRENT reported results are being visibly weighed down by the cost of an expansion the company has ALREADY undertaken, AND justify carr...YES The transcript shows management explicitly linking the current EBITDA decline to the hiring expansion already completed ("increased the number of FlyMates by over 50% during the past year" and "added over 100 new FlyMates within the sales, marketing and product functions"), while framing the spending as a deliberate, ongoing 2022 investment plan that is already delivering observable results through record client adds (130), pipeline growth, and strong ARR signings.
EVGO · Q2 2022 → YESThe question is: Does management acknowledge that the company's CURRENT reported results are being visibly weighed down by the cost of an expansion the company has ALREADY undertaken, AND justify carr...YES Management describes concrete expansion already underway—170 stalls placed in Q2, total stalls at 2,397 with 460 under construction, pipeline at 3,669, CapEx jumped to $44 million to accelerate deployment, and G&A ramping personnel to support growth—while directly tying the resulting negative adjusted EBITDA of -$19.8 million to that deliberate build-out.